Invivyd (IVVD) Competitors $0.87 -0.04 (-4.03%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.87 +0.01 (+0.58%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. RAPP, ERAS, DNA, ATAI, UPXI, TNGX, SEPN, PGEN, PRTC, and CMPSShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Rapport Therapeutics (RAPP), Erasca (ERAS), Ginkgo Bioworks (DNA), Atai Life Sciences (ATAI), Upexi (UPXI), Tango Therapeutics (TNGX), Septerna (SEPN), Precigen (PGEN), PureTech Health (PRTC), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors Rapport Therapeutics Erasca Ginkgo Bioworks Atai Life Sciences Upexi Tango Therapeutics Septerna Precigen PureTech Health COMPASS Pathways Invivyd (NASDAQ:IVVD) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings. Does the media favor IVVD or RAPP? In the previous week, Invivyd and Invivyd both had 2 articles in the media. Invivyd's average media sentiment score of 1.84 beat Rapport Therapeutics' score of 1.10 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rapport Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, IVVD or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Invivyd. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$36.69M2.84-$198.64M-$1.20-0.72Rapport TherapeuticsN/AN/A-$34.79M-$3.45-3.51 Is IVVD or RAPP more profitable? Rapport Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -155.33% -114.88% Rapport Therapeutics N/A N/A N/A Do institutionals and insiders hold more shares of IVVD or RAPP? 70.4% of Invivyd shares are held by institutional investors. 25.4% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate IVVD or RAPP? Invivyd currently has a consensus target price of $5.85, indicating a potential upside of 573.19%. Rapport Therapeutics has a consensus target price of $32.67, indicating a potential upside of 169.97%. Given Invivyd's stronger consensus rating and higher probable upside, equities analysts clearly believe Invivyd is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer IVVD or RAPP? Invivyd received 23 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. Likewise, 86.67% of users gave Invivyd an outperform vote while only 75.00% of users gave Rapport Therapeutics an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes2686.67% Underperform Votes413.33%Rapport TherapeuticsOutperform Votes375.00% Underperform Votes125.00% SummaryInvivyd beats Rapport Therapeutics on 11 of the 15 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.25M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.4433.3227.1220.06Price / Sales2.84469.84412.30157.10Price / CashN/A168.6838.2534.64Price / Book0.543.457.064.70Net Income-$198.64M-$72.35M$3.23B$247.88M7 Day Performance-6.06%6.23%2.86%2.63%1 Month Performance3.72%16.53%9.07%6.36%1 Year Performance-47.33%-16.90%31.45%14.05% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.8114 of 5 stars$0.87-4.0%$5.85+573.2%-46.4%$104.25M$36.69M-0.44100Positive NewsRAPPRapport Therapeutics1.7468 of 5 stars$12.71+0.4%$32.67+157.0%N/A$463.89MN/A-3.68N/APositive NewsERASErasca2.7685 of 5 stars$1.63+1.9%$4.57+180.5%-32.4%$461.76MN/A-1.96120Positive NewsDNAGinkgo Bioworks0.7684 of 5 stars$7.84+3.3%$5.77-26.4%N/A$458.89M$237.42M-0.60640Positive NewsGap UpATAIAtai Life Sciences3.3091 of 5 stars$2.28-5.4%$8.67+280.1%+68.9%$456.77M$1.86M-2.8180Analyst RevisionGap UpUPXIUpexi1.0865 of 5 stars$11.99+7.0%N/A+29.5%$454.60M$16.56M0.00130Short Interest ↑Gap UpTNGXTango Therapeutics1.9328 of 5 stars$4.16-2.3%$12.20+193.3%-31.5%$450.92M$40.99M-3.5390News CoveragePositive NewsAnalyst RevisionGap UpHigh Trading VolumeSEPNSepterna2.2485 of 5 stars$10.11-1.0%$27.00+167.1%N/A$450.48M$977K0.00N/APositive NewsAnalyst RevisionPGENPrecigen4.1585 of 5 stars$1.50flat$5.50+266.7%-8.5%$442.77M$4.20M-2.73190Positive NewsAnalyst RevisionGap UpPRTCPureTech Health2.2401 of 5 stars$18.31-3.6%$45.00+145.8%-35.4%$439.79M$4.32M0.00100Positive NewsCMPSCOMPASS Pathways2.653 of 5 stars$4.67-2.7%$18.83+303.3%-28.2%$436.94MN/A-2.12120Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies RAPP Competitors ERAS Competitors DNA Competitors ATAI Competitors UPXI Competitors TNGX Competitors SEPN Competitors PGEN Competitors PRTC Competitors CMPS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
